Market Introduction
The MEA protein binding assay market has been further segmented into the UAE, Saudi Arabia, South Africa, and rest of middle east and Africa. The market for protein binding assay in the MEA is anticipated to grow at a CAGR 9.3% during the forecast period; this growth is attributed to increase in pharmaceutical R&D expenditure, increase in developments in the pharmaceutical and biotechnological industries, and the increasing focus on suppressing the expenditure being incurred on the drug discovery & their manufacturing and the availability of various advanced technologies utilized for protein binding. In recent times, protein binding assay holds a promising future as pharmaceutical firms. Saudi Arabia is a very important country in the field of clinical research and the CRO. The health care system is strongly developed. Now more sponsors are developing their medical and research team in the Kingdom. Clinical research has been covered and regulated by the Saudi FDA (SFDA) since 2010, and start-up time tends to decrease even more. The bio/pharmaceutical outsourcing industry has seen an increase in R&D demand as a result of the COVID-19 pandemic. This increase in demand, as well as other pandemic impacts, such as increasing demand for clinical trials and outsourcing services, have led some CROs to shift focus and adjust their operations. The pandemic has pushed more pharmaceutical companies and regulators to use new technologies for remote quality audits and inspections, thus driving positive changes in the pharma industry. The growing pharmaceutical R&D activities in the region boost the adoption of protein binding assays in drug discovery & development likely to drive the market growth
As per Worldometer data, South Africa (2,408,525), Israel (868,045), the UAE (676,251), and Saudi Arabia (522,108) are among the worst-affected countries by the COVID-19 disease in the Middle East and Africa, as of July 2021. The pandemic has boosted the demand for medical devices that can be used in a home care setting. There has been a rise in numbers of patients admitted to intensive care units (ICU), and medications imposing multiple diagnostic and therapeutic challenges on stressed healthcare systems, which has led to a rise in demand for medical devices. According to the World Bank forecasts, remittances to the MENA region are projected to fall sharply by 19.6%, after total of USD 42 billion in 2020 with a 2.6% increase in 2019. For the first time in decades, MENA countries are facing a common issue with no political or religious agenda. The advent of high-throughput screening of approved compounds and small molecules has allowed researchers to effectively evaluate large drug libraries for checking their in vitro antiviral activity against novel targets. Russia has developed a new treatment for COVID-19 patients and is soon going to conduct trial in partnership with Saudi Arabian health. Thus, such increased research and development activities boost the adoption of protein binding assays in drug discovery and development in the Middle East and Africa.
Market Overview and Dynamics
The protein binding assay market in MEA is expected to grow from US$ 16.41 million in 2021 to US$ 30.64 million by 2028; it is estimated to grow at a CAGR of 9.3% from 2021 to 2028. Growing Label- Surge in CRO Industry in emerging markets; contract research organizations (CROs) have rapidly emerged as a force in drug development and clinical trial recruiting. emerging countries are emerging as attractive outsourcing locations for drug manufacturers. Low manufacturing and operating costs are driving the growth of the CRO industry. Recent growth in the pharmaceutical industry indicates a positive outlook for protein binding assay market. The CRO industry is experiencing strong growth owing to surging technological innovations, changing regulations, and increasing outsourcing levels. There is a continuous growth in scientific base and capabilities owing to the growing contribution of clinical research, centralized healthcare institutions, well-qualified and highly motivated investigators, and excellent clinical trial facilities.
Key Market Segments
Based on technology is segmented into ultracentrifugation ultrafiltration, equilibrium dialysis, surface plasmon and others. In 2020, the equilibrium dialysis segment is likely to hold the largest share of the market, by technology. Based on the end user was segmented into contract research organization, pharmaceutical & biotechnology companies, and research & diagnostic laboratories. In 2020, the pharmaceutical & biotechnology companies segment is likely to hold the largest share of the market, by end user.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the protein binding assay market in MEA are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Biotium, Inc, Eurofins Scientific, General Electric Company, MERCK KGaA, MicroConstants, Inc, Ltd, Sartorius AG, SOVICELL GMBH, and THERMO FISHER SCIENTIFIC INC. among others.
Reasons to buy report
MEA PROTEIN BINDING ASSAY MARKET SEGMENTATION
By Technology
By End User
By Country
Company Profiles